WebCurrently working as Sr Biopharmaceutical Representative at AbbVie Inc. AbbVie combines advanced science, expertise and passion to solve the world’s most serious health issues and have a remarkable impact on people’s lives. I'm responsible for promoting the Launch of Venclyxto (venetoclax). Venclyxto is a cancer medicine … Web10 apr. 2024 · Treatment of AML consists of induction, consolidation, and maintenance. Induction involves cytarabine-based therapy (7 days continuous IV) and an anthracycline (idarubicin, doxorubicin; 3 days of ...
Targeting of epigenetic co-dependencies enhances anti-AML …
WebVenetoclax inhibits and blocks this activity of the BCL-2 protein, causing cell death of the leukaemia cells. It is also used to treat another type of leukaemia called chronic … Web20 aug. 2024 · This phase II trial studies how well azacitidine and venetoclax work in treating patients with acute myeloid leukemia that is in remission. Drugs used in … graph p x
The efficacy and safety of venetoclax and azacytidine …
WebCytogenetics With or Without TP53 Mutations Treated With Venetoclax and Azacitidine. Clin Cancer Res. 2024;28(24):5272-5279. 13. Stahl M, Menghrajani K, Derkach A, et al. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2024;5(5):1552-1564. 14. Web13 apr. 2024 · When dosed in combination, BMF-219 and BMF-500 show beneficial effects affording higher cell killing at lower concentrations. Repeated experiments revealed patterns of increased cell killing is achieved when trametinib, MEK inhibitor, and venetoclax, BCL2 inhibitor, are combined with BMF-219 treatment. Conclusions: Web1 jun. 2024 · Venetoclax is a potent oral B-cell lymphoma 2 (BCL2) inhibitor that is effective at eliminating CLL, including high-risk del17p/mutated- TP53 CLL and CLL refractory to … graphql and authorization